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Abstract
Sequencing the first human genome in 2003 took 15 years and cost $2.7 billion.
Advances in sequencing technologies have since decreased costs to the point
where it is now feasible to resequence a whole human genome for $1000 in a
single day. These advances have allowed the generation of huge volumes of high-
quality human sequence data used to construct increasingly large catalogs of
both population-level and disease-causing variation. The existence of such
databases, coupled with a high-quality human reference genome, means we are
able to interrogate and annotate all types of genetic variation and identify
pathogenic variants for many diseases. Increasingly, sequencing-based
approaches are being used to elucidate the underlying genetic cause of
autoimmune diseases, a group of roughly 80 polygenic diseases characterized by
abnormal immune responses where healthy tissue is attacked. Although sequence
data generation has become routine and affordable, significant challenges remain
with no gold-standard methodology to identify pathogenic variants currently
available. This review examines the latest methodologies used to identify
pathogenic variants in autoimmune diseases and considers available sequencing
options and subsequent bioinformatic methodologies and strategies. The
development of reliable and robust sequencing and analytic workflows to detect
pathogenic variants is critical to realize the potential of precision medicine
programs where patient variant information is used to inform clinical practice.
INTRODUCTION
Autoimmune diseases are a group of roughly 80 polygenic
diseases characterized by aberrant immune responses where
healthy tissues, organs and cells are attacked. This is caused by
the failure of immune systems to respond appropriately to
self-antigens and results in damage to tissues and organs.
Autoimmune diseases are a heterogenous group of diseases
with regard to pathogenicity, heritability and prevalence, and
currently few effective therapies exist.1 Some of the most
common autoimmune diseases are rheumatoid arthritis, type
1 diabetes (T1D), inflammatory bowel syndrome, systemic
lupus erythematosus (SLE) and Sj€ogren’s syndrome.
Autoimmune diseases represent a global health burden
with an estimated occurrence rate of 4.5%, and
disproportionately affect females at a rate of 6.4%
compared with 2.7% for males.1 Prevalence rates of
autoimmune diseases are rising, with a recent report
from the British Society for Immunology estimating
disease incidence growth at a rate of 3%–9% annually.2
Prevalence of autoimmune diseases varies according to a
wide variety of environmental and genetic factors;
however, the influence of such factors varies considerably
across the family of autoimmune diseases. Gender is a
significant factor in some systemic conditions such as
SLE and Sj€ogren’s syndrome with 90% of cases occurring
in females, whereas T1D and Guillain–Barre syndrome
exhibit no gender bias.3 Geography also plays a role with
an estimated 1 in 12 people being affected by an
autoimmune disease in the Western Hemisphere,4 a
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higher estimate than the rest of the world. A smaller
study found that individuals in Finland have six times
higher rates of T1D compared with individuals from the
adjacent Karelian republic of Russia despite sharing the
same genetic background.5 Ethnicity also plays a major
role in many autoimmune diseases with significant
differences observed with regard to incidence rates and
disease severity.6 For example, African Americans are five
to nine times more likely to develop SLE than European
Americans and typically develop more severe SLE which
exhibits a greater number of manifestations and is more
damaging.7 However, other autoimmune diseases are
more prevalent in Northern Europeans, as they are more
susceptible to T1D than ethnic Chinese.8 Little is known
regarding the underlying mechanisms for the observed
disparities between ethnicities; however, differences in
human leukocyte antigen (HLA) regions are thought to
contribute.6
Although environmental factors are known to
contribute to autoimmune diseases, genetic factors are
increasingly recognized to play a key role.9 Many types of
autoimmune diseases such as inflammatory bowel
syndrome10 and SLE11 show familial clustering, and
subsequent twin studies also exhibit high concordance
rates among monozygotic twins.12 Heritability estimates
vary across autoimmune diseases, with a recent study of
pediatric age autoimmune cohorts estimating 86%
heritability for T1D at the high end compared with 43%
for Crohn’s disease at the low end.4 The high estimated
heritability and early successes in identifying pathogenic
variants from patient sequence data13 have led to
increasingly large genetic studies being undertaken. These
studies continue to link new genes to monogenic
autoimmune disorders, with the latest Inborn Errors of
Immunity report documenting 430 known defects, a gain
of 64 additional gene defects in the last 2 years alone.14
Early work to elucidate the underlying contribution of
genetic variation to autoimmune diseases focused on
increasingly large genome-wide association studies
(GWASs). GWASs successfully identified numerous risk
loci, and a review identified 819 unique loci across 136
separate GWASs.6 Although successful, GWAS was only
able to account for a small portion of the estimated
heritability in autoimmune diseases, meaning most
heritability remained unexplained. A possible explanation
for the missing heritability arises from a limitation of
GWAS, as it only examines common single-nucleotide
variants (SNVs). The advent of cheap sequencing allows
other variation types to be interrogated, with results
showing significant contribution to autoimmune diseases
from rare SNVs,15,16 indels,17 somatic mosaicism18 and
structural and copy number variation.19 In addition,
immune system–specific applications such as the
sequencing of HLA regions,20,21 T-cell receptors (TCR)18,22
and B-cell receptors (BCR)23 have helped to better
understand their unique role in autoimmune diseases.
Autoimmune diseases are also variable in response to
treatment and increasingly these differences are being
attributed to genetic variation.24 Individual patient
sequencing can help inform clinical practice, yet this
requires increasingly sophisticated bioinformatics software
and methodologies to reliably detect pathogenic variants.
This review focuses on the sequencing options and
bioinformatics methodologies currently used to discover
pathogenic variants that drive autoimmune diseases.
While sequence data generation is now routine, strategies
to effectively reduce the search space for pathogenic
variants are critical to the development of successful
personalized medicine programs for autoimmune diseases.
SEQUENCING OPTIONS
There is a wide variety of affordable high-throughput
sequencing technologies available to help identify variants
contributing to autoimmune diseases (Table 1).
Sequencing options for Mendelian disorders are
numerous and the most common approach is short-read
DNA-based methods that sequence either custom gene
panels, exomes or whole genomes. Gene panel sequencing
yields high-depth coverage across preselected genes of
interest by performing an initial capture step. However,
such approaches are limited as they presume an existing
knowledge of disease-implicated genes and limit novel
discoveries. Exome sequencing can capture over 95% of
all exons and splice site regions across all known genes
and is an extremely popular option, costing roughly one-
third of the cost of genome sequencing. The disadvantage
of exome sequencing is the inability to identify most
noncoding variants and the failure to reliably detect types
of variation larger than SNVs and small indels. Whole-
genome sequencing offers the most comprehensive and
unbiased view across all variation types; however, the
associated cost with this method is the highest among
available methods.
All high-throughput sequencing options generate large
volumes of raw data that make pathogenic variant
detection identification challenging. Additional options to
reduce the variant search space are often deployed
alongside short-read DNA-based methods. These include
sequencing patient RNA, adding unique molecular
identifiers (UMIs) to individual molecules, employing
single-cell technologies to detect somatic and immune
system subset–specific variation and utilizing long-read
technologies such as Oxford Nanopore or PacBio.
UMI sequencing is commonly used to sequence
heterogenous cell populations containing mixtures of
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both wild-type and disease-causing cells. The technology
works by affixing a UMI to each individual input DNA
molecule, often prior to PCR amplification. After
sequencing, the software deconvolutes the UMIs and
reads sharing UMIs are pooled together for analysis, with
each group representing an individual input DNA
molecule.25 UMI sequencing is often combined with
single-cell omics technologies, which are able to analyze
large numbers of individual cells simultaneously. Single-
cell technologies are changing our understanding of
immunology by allowing us to examine many aspects of
the immune system subsets in great detail, including their
inherent variation.26 For example, a recent study
identified lymphoma driver mutations in a specific cell
lineage that was producing pathogenic autoantibodies.18
RNA sequencing is increasingly employed in tandem
with DNA sequencing to identify potential noncoding
pathogenic variants. The functional information provided
by RNA sequencing identifies dysregulated genes, many
of which result from genetic changes, which allows the
closer examination of the small number of candidate
genes of interest. A recent study increased diagnostic
rates by 35% relative to genome sequencing alone by
identifying pathogenic variants responsible for exon
skipping, exon expansion and intronic splice gains.27
With RNA sequencing, it is critical to only sequence
disease-specific tissue and to only compare samples across
identical tissue types. This is not possible for all diseases,
which limits its widespread applicability.
Long-read sequencing is increasingly recognized as a
valuable tool to resolve larger complex genetic variants
such as repeat expansions, copy number and structural
variation and also for sequencing the TCR/BCR and HLA
regions. While pathogenic variation detection using long-
read sequencing has been most successful in cancer and
neurological disorders detection thus far,28 researchers are
now applying this approach in autoimmune diseases.
Long-read sequencing may also be used in pseudogene
discrimination, with a recent study developing a
robust diagnostic application that is able to
unambiguously sequence three autoimmune diseases
genes (IKBKG, IRAK4 and MYD88) while bypassing the
IKBKGP1 pseudogene.29 Currently, the major issues that
prevent the uptake of long-read sequencing are the
increased per-base cost and the higher error rates relative
to short-read sequencing. However, both cost and error
rates are continually improving.
Several sequencing applications are specific to the
immune system. Deep sequencing of the HLA, TCR and
BCR regions is now possible, with variation in these
regions implicated in causing autoimmune diseases.18,20,21
Although it is possible to identify HLA, TCR and BCR
sequence using standard approaches, these applications
yield better results with additional capture steps and
bespoke software. For example, resolving HLA types is
challenging using standard approaches because of low
HLA sequence coverage and the incomplete
representation of the HLA region in the human reference
genome, resulting from its highly polymorphic nature. As
such, many companies now offer deep sequencing of the
HLA region by providing specific capture assays able to
yield high-resolution phased HLA sequences. Similarly,
deep-sequencing TCR and BCR clonotypes require
additional steps including target enrichment, multiplex
PCR or molecular tagging prior to sequencing. TCR/BCR
sequencing is further confounded as a result of the full-
Table 1. Sample of sequencing options available for variant detection in autoimmune diseases
Sequencing type Detectable variation Advantages Limitations
GWAS Loci on GWAS chip Cheap/large studies possible Only common SNVs
Whole genome All variant types: coding and noncoding All variant types detectable Expensive relative to targeted
approaches
Exome SNV and small indel in coding regions Capture most coding regions No noncoding or large variation
Gene panel SNV and small indel in panel genes High-depth coverage for panel genes Nothing novel is detectable
Molecular
tagging
Somatic and cell subset–specific variants Analyze individual input molecules Additional library
preparation / custom software
Single cell Somatic and cell subset–specific variants Analyze individual cells Additional library
preparation / custom software
HLA typing HLA genotypes High-resolution phased HLA genotypes Immune system specific
BCR B-cell clonotypes Construct and observe changes in BCR Immune system specific
TCR T-cell clonotypes Construct and observe changes in TCR Immune system specific
Transcriptome Aberrant splicing/gene fusions/coding SNV Observe effect of variants on genes Miss rare transcripts/added expense
Long reads All variant types: coding and noncoding Resolve large variants/full gene transcripts Higher error rate and higher
per-base cost
BCR, B-cell receptor; GWAS, genome-wide association study; HLA, human leukocyte antigen; SNV, single-nucleotide variant; TCR, T-cell
receptor.
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length V(D)J chain being 330 bp; this is longer than
individual short reads and thus requires custom software
to accurately reconstruct B- and T-cell clonotypes.
SAMPLE SELECTION STRATEGIES
In addition to sequencing options, careful patient sample
selection has been shown to increase the success rates in
pathogenic variant identification. While sample selection
is not always an option, studies have shown that for
singleton samples it is optimal to focus on early onset
cases with extreme phenotypes and a clearly defined
clinical phenotype.30 These strategies have been used to
identify a growing number of pathogenic variants in
singleton samples which are deposited into clinical
repositories that serve to link patient data from around
the world. Searching across samples is a powerful
approach, with a recent study describing a new immune
dysregulation resulting from the linking of two singleton
studies from unrelated cohorts in Australia and Japan.31
Compared with singleton sequencing, the most
effective method for detecting pathogenic variants is
sequencing multiple individuals within a family or
pedigree. Sequencing a pedigree generates family-wide
variant information, such as disease inheritance pattern,
compound heterozygosity and genome phasing, later used
for additional variant prioritization.32 Another immediate
benefit of this approach is the ability to catalog familial
variation, often incorrectly assumed to be pathogenic
because of its absence in databases of population-level
variation. The greatest successes with pedigree sequencing
come from sequencing trios, which consist of an affected
child and unaffected parents. In such cases, it is likely the
causal variant will be a de novo mutation in the affected
child, which serves to greatly reduce the variant search
space. This approach is also informative, with larger
pedigrees exhibiting complex inheritance patterns, as
variants shared between affected individuals are
prioritized and variants shared with unaffected family
members are deprioritized. Collectively, these sample
selection strategies are able to greatly reduce the causal
variant search space.
VARIANT DETECTION WORKFLOW
A typical variant detection analysis workflow consists of
six major analysis steps: data quality control/adapter
trimming, read alignment, alignment file preprocessing,
variant detection, variant annotation and variant
prioritization. The early workflow steps generally require
more computation time and work with larger data sets,
whereas the later workflow steps require more domain-
specific analyses and offer a greater variety of software
choices (Figure 1).
Figure 1. Variant detection workflow. SNV, single-nucleotide variant.
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While there is currently no accepted end-to-end gold-
standard methodology for identifying pathogenic variants,
analysis steps leading to the generation of variant calls
have become relatively standardized. By contrast, variant
annotation and prioritization are specific to individual
variant detection workflows and often contain analysis
steps specific to the disease being studied. A sample of
common open-source software packages for each
workflow step is listed in Table 2.
The first analysis step is sequence data quality control
and adapter trimming. Trimmomatic33 is a popular tool
used for this purpose, which identifies and removes
adapter sequence, trims low-quality bases from the end of
reads and removes reads with a high total fraction of
low-quality bases using a sliding window approach.
Following data quality control, reads are aligned to the
gold-standard reference human genome GRCh38.p13
using a short-read aligner such as Burrows-Wheeler
Aligner (BWA).34 BWA first constructs an index of the
reference genome and aligns individual reads to the index
by anchoring small seed subsequences that allow base
mismatches and gaps to account for sequencing errors.
Local read alignments are expanded as far as possible
around each matching seed and the highest scoring
alignment is selected. Aligners output a compressed
alignment file in binary alignment map (BAM) format
which is then optimized for variant calling. This consists
of marking potential duplicate reads, realigning reads
around candidate indels to account for local
misalignments and recalculating the base qualities to
account for systematic errors made by the sequencing
machine during the estimation of base call accuracies.
The processed BAM file is used as input to the variant
calling algorithms where different types of variation are
detected relative to the human reference genome. Variant
detection algorithms aim to differentiate real genetic
variation from experimental error by employing statistical
methodologies specific to each type of variation, with the
exception being the simultaneous detection of SNVs and
small indels by algorithms such as Genome Analysis
Toolkit (GATK).35 Most variant detection algorithms
assign a variant quality score and apply a hard cut-off
when generating a list of true variants. However, an
increasingly popular approach is to perform variant
“group calling,” where variants are detected
simultaneously across a larger cohort. Group variant
calling can be used to identify missed variants that would
otherwise fall just below the quality cut-off scores because
of issues such as low base coverage or skewed allele
frequency ratios. Another increasingly common approach
shown to improve variant calling quality is to run
multiple algorithms and then take a consensus of variant
calls.39,40 This approach is particularly relevant in clinical
variant detection workflows where false-negative variants
are of the greatest concern.
Variant detection algorithms output raw variant lists in
variant call format which are filtered to remove candidate
false positives. Variants are generally filtered based on
variant context characteristics such as low-quality
alignment scores, low read depth, low-quality base scores
or variant clustering. Yet, some algorithms such as
Variant Quality Score Recalibration (VQSR) from GATK
employ a machine learning approach that uses a variant
truth set to differentiate true- and false-positive variants.
Generating raw variant lists for large sequence data sets
(such as whole genomes) requires large computational
resources and storage, typically 1000 CPU hours and 500-
GB storage. In terms of variant numbers, a genome
contains roughly 4 million SNVs, 400 000 small indels
and 100 000 copy-number variations/structural
variations. While generating these high-quality variant
calls requires significant computational resources, the
workflow is relatively standardized: the challenge is in
reducing the variant search space to identify the variants
most likely to be pathogenic. The approaches for
annotating and prioritizing variants are less standardized
Table 2. Common software options for analysis steps in variant detection workflow
Analysis step Example software URL
Data quality control/trimming Trimmomatic33 http://www.usadellab.org/cms/?page=trimmomatic
Read alignment BWA34 http://bio-bwa.sourceforge.net/
BAM preprocessing Picard https://broadinstitute.github.io/picard/
Variant calling (SNV/indel) GATK35 https://gatk.broadinstitute.org/hc/en-us
Variant calling (UMI tags) DeepSNVMiner25 https://github.com/mattmattmattmatt/DeepSNVMiner
Variant calling (structural variation/copy-number variation) Manta36 https://github.com/Illumina/manta
Variant calling (Pedigree) VASP32 https://github.com/mattmattmattmatt/VASP
Variant annotation Variant Effect Predictor37 https://ensembl.org/info/docs/tools/vep/index.html
Variant prioritization PolyPhen-238 http://genetics.bwh.harvard.edu/pph2/
SNV, single-nucleotide variant; UMI, unique molecular identifier.
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than earlier steps and often combine publicly available
software and data sets with custom code and annotations.
Collectively, software-based strategies to prioritize
pathogenic variants are combined with sequence-based
and sample selection strategies that enrich for pathogenic
variants to form the basis of a successful pathogenic
variant detection workflow (Figure 2).
The first step in variant annotation is to determine the
impact of the variant on genes or other important
genomic features. This requires a reliable gene model
such as Ensembl or RefSeq along with a variant
annotation tool such as Ensembl’s Variant Effect
Predictor.37 For SNVs, those classified as missense,
nonsense or splice sites mutations are prioritized, with
missense mutations further run through software such as
PolyPhen-2,38 which predicts the likely impact of the
amino acid substitution on protein function. These
predictive algorithms consider factors such as
evolutionary sequence conservation, protein structure and
overlap with protein features such as binding sites. While
these algorithms generally have low false-negative rates,
they suffer from high false positives, with a recent study
finding that over 50% of predicted damaging missense
mutations being functionally benign.41 For other variant
types, small indels are prioritized if they overlap genes
and cause frameshift mutations, whereas larger variants
are examined in terms of knocked out genes/exons or
potential gene fusions. Variants are also compared with
catalogs of both population-level variation (e.g. dbSNP42/
gnomAD43) and disease-specific variants (e.g. ClinVar44).
With population-level variant repositories, comparing
with ethnically matched allele frequencies is critical to
account for the often-large allele frequency differences
observed between ethnic groups. The prioritization
strategy differs depending on the nature of the data set
with variants’ overlapping entries in disease databases
taken forward while variants found to occur at high allele
frequency in the general population removed from
further consideration.
The final step in the process is amalgamating all the
information into prioritized ranked lists that contain the
variants most likely to be pathogenic. Software such as
GEMINI45 attempts to generate prioritized variant lists;
however, in general, this process is largely unsuitable for
external software because of the development of custom
in-house methodologies employed throughout the
workflow. Ultimately any successful workflow will score
true pathogenic variants highly which allows domain
experts to identify pathogenic variants through manual
interrogation of a small number of candidates.
Figure 2. Strategies to reduce the variant search space for pathogenic variants. HLA, human leukocyte antigen; TCR, T-cell receptor.
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Such workflows are increasingly forming the basis of
personalized medicine programs, such as the Centre for
Personalised Immunology in Australia or the Relent
Project in Europe. Precision medicine programs are
broader in scope than variant detection workflows and
begin with patient recruitment and culminate in the
creation of a concise clinical variant report used to
inform clinical decision making (Figure 3).
For complex diseases with heterogenous genetic causes
and confounding environmental factors, such as
autoimmune diseases, the default resultant variant lists
are often large and unsuitable for manual interrogation
and require additional custom analyses to further reduce
the variant search space. Additional measures to further
reduce the variant search space for autoimmune diseases
include immune system–specific annotation, sequencing
the HLA region and sequencing the TCR/BCR regions
(Table 3).
The most common approach in autoimmune diseases
is to annotate variants with immune system–specific
data sets such as ImmGen,54 InnateDB,55 IMSEQ,52
Immuno Polymorphism Database,56 Infevers57 and
locus-specific LOVD databases.58 These databases
contain information covering a variety of aspects of the
Figure 3. Personalized medicine workflow. SNV, single-nucleotide variant.
Table 3. Resources to reduce variant search space in autoimmune diseases
Analysis type Software/database URL
HLA sequencing HLAminer46 https://www.bcgsc.ca/resources/software/hlaminer
HLA sequencing seq2HLA47 https://bitbucket.org/sebastian_boegel/seq2hla/src/default/
HLA sequencing OptiType48 https://github.com/FRED-2/OptiType
HLA sequencing PHLAT49 https://sites.google.com/site/phlatfortype/
TCR/BCR sequencing MiXCR50 https://mixcr.readthedocs.io/en/master/
TCR/BCR sequencing VDJPuzzle51 https://github.com/simone-rizzetto/VDJPuzzle
TCR/BCR sequencing IMSEQ52 http://www.imtools.org/
BCR sequencing IgDiscover53 https://github.com/NBISweden/IgDiscover/
Annotations ImmGen54 http://www.immgen.org/
Annotations InnateDB55 http://www.innatedb.com
Annotations Immuno Polymorphism Database56 https://www.ebi.ac.uk/ipd/index.html
Annotations Centre for Personalised Immunology https://database.cpi.org.au/cpi28/
Annotations Infevers57 https://infevers.umai-montpellier.fr/web/
Annotations LOVD 2.058 http://www.lovd.nl
BCR, B-cell receptor; HLA, human leukocyte antigen; TCR, T-cell receptor.
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immune system which can be used to prioritize
pathogenic autoimmune diseases variants. For example,
ImmGen contains gene expression data for immune cells
in mouse, whereas Infevers contains information on
hereditary autoinflammatory disorder mutations.
Although such resources are useful, an overreliance on
any single data source is ill advised, as entries are often
inconsistent because of evaluations made using
incomplete functional evidence. To illustrate, a follow-
up study of 239 annotated disease-causing variants listed
in the Human Gene Mutation Database59 was only able
to recapitulate the results for 7.5% of the entries. This
lack of reproducibility highlights the importance of
working as much as possible with up-to-date resources
that are expertly curated and rigorous in their inclusion
criteria such as the Inborn Errors of Immunity report.14
Sequencing applications such as deep sequencing of the
BCR, TCR and HLA regions are unique to studies of the
immune system and require application-specific software.
While software specific to these applications is maturing,
recent benchmarking reviews of the available software for
both HLA sequencing60 and TCR sequencing61,62 report
high levels of variability in overall software performance.
Recent reviews of BCR sequencing also discuss available
software; however, individual algorithms were not
benchmarked in these studies.63,64 Both reviews stress the
importance of using the extensive IMGT database56 for
clonotype assignment and the importance of constructing
a complete catalog of all allelic variants using algorithms
such as IgDiscover.53 In the review of HLA typing
software, six algorithms were run across a “gold-
standard” data set, and found OptiType48 to be the most
accurate at 99%. However, the algorithm only detects
Class I HLA genotypes, thus limiting its clinical utility.
Among algorithms able to detect both Class I and II HLA
genotypes, PHLAT49 had the highest accuracy at 81%: it
was noted that this is likely insufficient for clinical utility,
and a consensus software approach was proposed as a
possible hybrid solution.40 In the review of TCR
sequencing software, the first study generated an in silico
data set and assessed clonotype detection, CDR3
identification, error correction and gene segment
assignment accuracy.61 This study found that not all
algorithms were able to run all four subanalyses and that
the performances varied greatly across individual
algorithms, particularly for gene assignment and error
correction. The second study performed a similar
analysis62 and concluded that no single tool performed
optimally for all types of analyses but recommended
MiXCR50 if limited to a single analysis. All review studies
note that superior results can be obtained using UMIs;
however, none of the software assessed in the previous
studies was able to incorporate this information.
Lastly, an illustrative example is described where a
novel pathogenic variant resulted in the description of a
new syndrome characterized by global immune
dysregulation. The variant was added to the Inborn
Errors of Immunity database in 2019. In this study, two
unrelated patients from Australia and Japan exhibited
similar phenotypes resulting in the destruction of
lymphocytes that lead to excessive inflammation.31 Both
patients were exome sequenced and analyzed using an
existing variant detection pipeline32 which identified a
candidate causal heterogeneous variant in the IKBKB
gene (inhibitor of nuclear factor kappa-B kinase subunit
beta). The variant was prioritized as it was novel, resulted
in a missense mutation that was predicted to be
damaging and occurred in an active site of IKBKB, a gene
which was previously implicated in causing combined
immune deficiency.65 The variant was confirmed with
Sanger sequencing to replicate the result using the
current gold-standard sequencing method. Further
evidence was provided for the Australian patient by
sequencing the unaffected parents which, following
confirmation of paternity, demonstrated that the
mutation had arisen de novo in the patient. While the
evidence was substantial, functional validation was
required using CRISPR–Cas [clustered regularly
interspaced short palindromic repeats (CRISPR)–
CRISPR-associated] technology to engineer the exact
mutation into a mouse model which generated a similar
immunodeficiency phenotype to the observed patients.
This example highlights the value of using sequencing
technologies to elucidate the underlying genetic cause of
autoimmune diseases.
FUTURE APPROACHES
This review discusses the current landscape in high-
throughput sequencing and bioinformatic workflows for
pathogenic variant detection in autoimmune diseases.
Sequence-based approaches continue to grow, with an
increasing number of precision medicine initiatives
around the world focused on autoimmune diseases.
While such initiatives are currently limited to short-read
DNA-based sequencing that use either gene panels,
exomes or whole genomes, increasingly long-read
sequencing, single-cell technologies, transcriptome
sequencing, immune profiling and molecular tagging
techniques are being incorporated. Looking beyond the
current approaches, researchers are now recognizing the
impact of the epigenome66 and the microbiome67 on
autoimmune diseases and in the future will integrate
these data types into workflows. Combining the disparate
data types will require a new generation of complex
bioinformatics software and statistical methodologies able
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to quickly and efficiently elucidate the cause of
autoimmune diseases.
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